SaNOtize Research and Development said that it has gotten approval from Health Canada to move ahead with two Phase 3 trials of its nitric oxide nasal spray for the prevention and treatment of COVID-19. The company also said that it has submitted a new drug submission to the Canadian regulators under a special Health Canada program allowing for rolling review of applications for drugs to treat COVID-19. In March 2021, SaNOtize said that it would apply for emergency use authorization for the nasal spray in both Canada and the UK.
The company will conduct separate trials of the nasal spray for the prevention of COVID-19 and for the treatment of early COVID-19. Enrollment for the prevention trial will start first.
SaNOtize Co-founder and Chief Science Officer Chris Miller said, “We are grateful for Health Canada’s fast response, and we are moving as quickly as possible to start the trial and enroll volunteers for Phase 3 trial here in Canada and elsewhere in the world.”
Read the SaNOtize press release.
